Related references
Note: Only part of the references are listed.Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution-A Simulation Study
Til Stuermer et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2010)
Rituximab A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Gillian M. Keating
DRUGS (2010)
Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data
Jack Hadley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
Pau Abrisqueta et al.
BLOOD (2009)
Plasma quantitation of JAK2 mutation is not suitable as a clinical test: an artifact of storage
Mohamed E. Salama et al.
BLOOD (2009)
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century
Hermann Brenner et al.
BLOOD (2008)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Ethnic Variations in Diagnosis, Treatment, Socioeconomic Status, and Survival in a Large Population-based Cohort of Elderly Patients With Non-Hodgkin Lymphoma
Michael Wang et al.
CANCER (2008)
Racial and ethnic differences in breast cancer survival - How much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics?
Elana Curtis et al.
CANCER (2008)
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods
T Stürmer et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review
BR Shah et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores:: Nonsteroidal antiinflammatory drugs and short-term mortality in the elderly
T Stürmer et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2005)
Technology diffusion, hospital variation, and racial disparities among elderly Medicare beneficiaries 1989-2000
PW Groeneveld et al.
MEDICAL CARE (2005)
Rituximab - A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
GL Plosker et al.
DRUGS (2003)
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
D Huhn et al.
BLOOD (2001)
Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Development of a comorbidity index using physician claims data
CN Klabunde et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
Share Paper
